Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 23,865 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 23,865 shares of Maze Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $26.05, for a total value of $621,683.25. Following the sale, the chief executive officer owned 319,079 shares in the company, valued at $8,312,007.95. This represents a 6.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Up 0.7%

Shares of Maze Therapeutics stock traded up $0.19 on Wednesday, hitting $26.60. 657,539 shares of the company’s stock traded hands, compared to its average volume of 688,291. The stock has a market cap of $1.47 billion, a P/E ratio of -10.51 and a beta of 2.27. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The firm’s 50-day moving average is $25.67 and its 200 day moving average is $36.25. Maze Therapeutics, Inc. has a 52-week low of $9.83 and a 52-week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. Equities analysts anticipate that Maze Therapeutics, Inc. will post -2.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on MAZE shares. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. HC Wainwright increased their price target on shares of Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. BTIG Research reiterated a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Truist Financial lowered their price objective on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, April 14th. Finally, Guggenheim upped their price objective on Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $66.00.

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada raised its holdings in shares of Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Maze Therapeutics in the 4th quarter valued at about $39,000. Ameritas Investment Partners Inc. boosted its holdings in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Maze Therapeutics during the 4th quarter valued at about $43,000. Finally, Russell Investments Group Ltd. raised its stake in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares during the period.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.